AstraZeneca aims to harmonize its share listings globally to enhance sustainable growth and investor reach, maintaining headquarters in the UK. Enhertu shows superior outcomes in early-stage ...

In today’s Pharmaceutical Executive Daily, we cover the impact of Novo Nordisk layoffs on its hometown in Denmark, GSK’s ...

AbbVie officially began construction on its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, ...

Genmab's acquisition of Merus for $8 billion enhances its oncology portfolio, promising growth and innovative therapies like ...

GSK appoints Luke Miels as CEO designate, set to lead the company into a pivotal growth phase starting January 2026.

The FDA has expanded Johnson & Johnson’s Tremfya (guselkumab) approval to children six years and older weighing at least 40 ...

The founder of InflaRX discusses lessons learned during the COVID-19 pandemic and how they’re being applied in a ...

While the MFN executive order targets drug companies for drug prices, Peter Rubin discusses how health plans also play a ...

Crinetics Pharmaceuticals celebrates FDA approval of Palsonify, the first oral treatment for acromegaly, enhancing patient ...

Regeneron's Evkeeza gains FDA approval for treating young children with homozygous familial hypercholesterolemia, addressing ...

Companies that have broken ground or begun construction on US manufacturing sites will be exempt from these tariffs.

Most Favored Nation drug pricing proposal aims to tie US medicine costs to lower European rates, but experts warn this approach could restrict patient access to lifesaving treatments, slow innovation, ...